Blog

The Market Changes Daily

We help you stay one step ahead.

Empathy Is a Healthy Workforce

Empathy Is a Healthy Workforce

Most executives agree that business success is tied to empathy in the workplace. Scripta offers companies one more way to show that they care. Most any HR professional will tell you that skyrocketing healthcare and prescription drug prices are necessarily complicating...

read more
PBMs Are Not Saving Anyone Money

PBMs Are Not Saving Anyone Money

It’s not insurers or Big Pharma sustaining rising prescription drug prices—it’s PBMs that are supposed to be saving patients and self-funded insurers money. Stop me if you’ve heard this one before—PBMs insist that drug prices would be even higher without them. Since...

read more
Pharmacy Data Analytics Can Help You SAVE

Pharmacy Data Analytics Can Help You SAVE

March 7, 2018 – If you are trying to control health benefits costs, the best place to start is with the data — and good pharmacy data analytics can improve plan design and save money. With the Benefits Pro Broker Expo due up next week in San Diego, we thought we’d...

read more
DUEXIS: The Cost of Convenience

DUEXIS: The Cost of Convenience

Did you know: Back in 2011, Horizon Pharma introduced a new, nonsteroidal anti-inflammatory drug with built-in stomach protection: DUEXIS. DUEXIS is ibuprofin (generic Motrin) 800mg plus famotidine (generic Pepcid) 26.6mg in one convenient tablet. It's meant to be...

read more
Old made new again (AGAIN)!

Old made new again (AGAIN)!

Did you know: Generic Paxil - paroxitine hydrochloride - has been available on the $4 plans for some time. We now have Pexeva, which is paroxitine mesylate. What's the difference? Clinically, I am not sure. The NIH, via Pub Med Health, groups it all as paroxitine. The...

read more
Generic Zyprexa is Here

Generic Zyprexa is Here

Did you know: Generic Zyprexa is here. 30 tabs of branded Zyprexa 20mg is $606. 30 tabs of the generic is only $15 (updated prices as of March 2018) at www.healthwarehouse.com! Not as fantastic a difference as when it first went generic - we track these things over...

read more
What is a steroid worth?

What is a steroid worth?

Did you know: Prednisone is available on the $4 plans. Thirty tabs is just $4, and ninety tabs is $10. Orapred ODT (prednisolone), on the other hand, is about $140 for 90 tabs (15mg or 30mg). There is, of course, a small clinical difference between prednisone and...

read more
We have a new sleep agent: Silenor

We have a new sleep agent: Silenor

Check it out: What's old is new again! Silenor is available in 3mg and 6mg tablets. The retail cost is about $446 per month for 30 tablets. Of course, Silenor is doxepin. Doxepin 10mg (generic) costs about $9 for 30 tablets. I'll let you do the math. Write it right,...

read more
Introducing Arimidex Direct

Introducing Arimidex Direct

Here's a new twist: Pharma has a new business model and, amazingly, the patients win! Arimidex went off patent in 2010. In response, drug maker AstraZeneca launched a direct-to-patient sales program for their branded breast cancer drug. The company's "Arimidex...

read more
The Many Faces of Welbutrin

The Many Faces of Welbutrin

Did you know: Wellbutrin is available in 8 different preparations. Aplenzin Budeprion XL Bupropion HCL 12 hour Bupropion HCL 24 hour Bupropion HCL Wellbutrin Wellbutrin SR Wellbutrin XL Bupropion HCL 12 hour is usually the least expensive - indeed, this generic is now...

read more
Caduet: Don’t Believe the Hype

Caduet: Don’t Believe the Hype

Did you know: Caduet is Lipitor + Norvasc. 30 tabs of Caduet (now generic) retails at $160 per month or $1920 per year. Consider substituting Simvastatin (atorvastatin) + amlodipine. The combination costs just $10 per month for both ($120 per year) at either Sam's...

read more
Are PBMs Fueling the Opioid Crisis?

Are PBMs Fueling the Opioid Crisis?

“At a time when the United States is in the grip of an opioid epidemic, many insurers are limiting access to pain medications that carry a lower risk of addiction or dependence, even as they provide comparatively easy access…

read more

Up is Down and Generics are Fair Game

August 6, 2017 – Out of public view, corporations are cutting deals that give consumers little choice but to buy brand name drugs - and sometimes pay more than they would for generics. The standard advice for consumers – “Always ask if there is a cheaper generic!” –...

read more
PCSK9 Inhibitors | Worth It? For Whom?

PCSK9 Inhibitors | Worth It? For Whom?

June 19, 2017 – Big Pharma, insurers, and doctors engage debate over efficacy and cost; meanwhile, patients struggle to access to an expensive new class of cholesterol drugs. Sumathi Reddy writing in the The Wall Street Journal offers a fascinating look at the tangled...

read more
FEUD! Big Pharma vs. Your PBM

FEUD! Big Pharma vs. Your PBM

May 31, 2017 – In a lawsuit that highlights the dangers of rising drug costs, PMBs and drugmakers reveal the games the games they play. In the midst of an opioid crisis that has become an epidemic, Kaleo Pharmaceuticals, a small private drugmaker, last year rasied the...

read more

EpiPen Price Gouging No Better

June 6, 2017 – A year ago, consumers and congressmen alike were shocked when Mylan raised the price of its EpiPen by 574%. Nothing has changed in the year since. The EpiPen has been around for decades—the device, known as an autoinjector was acquired by Mylan...

read more
Big Pharma Loves to Create Drama

Big Pharma Loves to Create Drama

May 18, 2017 – The FDA regulates direct-to-consumer marketing of pharmaceutical products, but it does not regulate “Disease Awareness” marketing on TV. One of the main characters in the daytime drama, General Hospital, has been battling polycythemia vera (PV), an...

read more
A 75% Markup for Being American

A 75% Markup for Being American

December 24, 2016 – America has always been known as “The Land of Opportunity.” New data shows that this is especially true for drug makers internationally. Large PBMs, such as CVS Caremark and Express Scripts are dropping lots of medications from their formularies in...

read more

Specialty Pharma Takes a Hit

December 22, 2016 – Analysts expect more uncertainty following a year in which the Martin Shkreli, Epipen, and Valeant scandals battered specialty pharma stocks. Analysts at Morgan Stanley have identified multiple factors that should concern investors as they assess...

read more

Drugmakers Eating Costs? (Fat Chance)

December 12, 2016 - The latest pay-for-performance arrangements between Big Pharma and PBMs are tied to exclusive or preferred-provider status. but how will they affect your employees? A new type of pay-for-performance agreement (what a notion!) has insurers and...

read more